The use of the prostate-specific antigen (PSA) test for screening symptomatic patients in the mid-1990s dramatically changed the profile of PCa patients, and within 10 years of its introduction, the average age at presentation was significantly lowered [2]. The gene discussed is KLK3; the disease is posterior cortical atrophy.